ArticleFrontiers in oncology2024
Development and validation of a nomogram prediction model for clinically significant prostate cancer combined with PI-RADS V2.1, MRI quantitative parameters and clinical indicators: a two-center study.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a multi-index nomogram prediction model for clinically significant prostate cancer(CSPCa) by combining the PI-RADS V2.1, quantitative magnetic resonance imaging (MRI) parameters and clinical indicators. Methods: A total of 1740 patients (75% in the derivation cohort and 25% in the internal validation cohort) and 342 patients (the external validation cohort) were retrospectively included in the MRI follow-up database of the First Affiliated Hospital of Kunming Medical University between January 2015 and April 2021,and Gejiu People's Hospital between January 2020 and December 2022.Important predictors of CSPCa in MRI-related quantitative parameters, PSA-derived indicators, and clinical indicators, such as age, were screened. The Net Reclassification Improvement Index(NRI),Integrated Discrimination Improvement Index(IDI), and clinical decision curve analysis (DCA) were calculated to compare the performances of the different models. Receiver operating characteristic(ROC) curves and clinical calibration curves were used to analyze and compare diagnostic effects. Results: The AUC value, best cut-off value, specificity, sensitivity and accuracy of model 1(PI-RADS + PSAD) derivation cohort were 0.935, 0.304, 0.861, 0.895 and 0.872, respectively. The AUC values of the internal and external validation cohorts for model 1 were 0.956 and 0.955, respectively. The AUC value, best cut-off value, specificity, sensitivity and accuracy of model 2(PI-RADS +PSAD + ADCmean) derivation cohort were 0.939, 0.401, 0.895, 0.853 and 0.882, respectively. The AUC values of the internal and external validation cohorts for model 2 were 0.940 and 0.960,respectively. After adding the ADCmean to the model, the NRI(categorical), NRI(continuous) and IDI values were 0.0154, 0.3498 and 0.0222, respectively. There was no significant difference between the predicted probability and actual probability (p> 0.05). Conclusion: Models 1 and 2 had reliable, efficient and visual predictive value for CSPCa. The ADCmean is an important predictive indicator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.